2 period. The committee recommends that protocol development be coordinated and streamlined by implementing the processes proposed by the Operational Efficiency Working Group.
The committee stresses the need to move beyond cooperation to integration by reorganizing clinical trial structures and operations into a truly national trials network. Among its recommended actions for improving overall operations, the report calls for consolidating many of the administrative functions and processes within the Cooperative Group Program, streamlining government oversight of trials, and enhancing collaboration among stakeholders. NCI should lead in instituting the necessary changes, but other federal agencies such as the Food and Drug Administration, as well as academic centers, community practices, and the pharmaceutical industry, will need to be involved in improving the system. NCI also should expand drug distribution and implement standardized case report forms and remote data capture systems to aid trial efficiency.
Incorporating Innovative Science
Progress in the treatment of cancer patients depends on the effective incorporation of scientific advances into clinical trials. For example, to achieve the goals of targeted cancer therapy, biomarkers (predictors of a response to a particular therapeutic intervention) increasingly are being used to select which treatment strategy is most likely to benefit individual patients. To advance this field, NCI should, among other actions, mandate that biospecimens collected from patients in the course of Cooperative Group trials be submitted to standardized central biorepositories supported by a national inventory and a defined peer-review process for accessing specimens for study.
The Cooperative Groups should lead in developing and testing innovative designs for clinical trials that evaluate multiple therapies, combinations of therapies, and biomarkers. The National Institutes of Health, including NCI, should take a
Building on a Strong Foundation
The IOM's report, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, reviews the roles of the various stakeholders involved in cancer clinical trials and recommends a series of changes across the board. The report's authoring committee envisions a dynamic system that efficiently responds to emerging scientific knowledge; involves broad cooperation of stakeholders; and leverages evolving technologies to provide high-quality, practice-changing research. Clinical trial participation would be desirable for patients and physicians because it would provide access to innovative therapies that reflect patient preferences and are reimbursed. The report emphasizes the need to maintain a robust, standing cancer clinical trials network by preserving the historical strengths of the Cooperative Group Program while improving components that are not working well. The following overarching goals should guide improvement efforts:
Improving the speed and efficiency of the 
Improving Speed and Efficiency
Clinical trials are complex endeavors that involve hundreds of steps and lengthy, iterative review processes by multiple oversight bodies with varying objectives and responsibilities. Inefficiencies in the processes used to develop, launch, and conduct clinical trials often lead to long delays. The average time required to design, approve, and activate a cancer clinical trial is two years. Given the pace at which new scientific findings are emerging, a trial concept may become outdated in that 3 more systematic, multidisciplinary, and dynamic approach when developing standards for new scientific methods and technologies used in trials, to ensure appropriate and consistent use.
Prioritizing and Supporting Trials
The increasingly complex environment in which cancer clinical trials are conducted has created considerable challenges for the Cooperative Group Program. Inefficient interactions among the various stakeholders are contributing to delays in the system. To increase the speed of advances in oncology care, NCI should shift its primary focus from oversight to the facilitation of Cooperative Group trials. As part of this effort, NCI should streamline processes for prioritizing, selecting, and supporting clinical trials and for enrolling patients quickly after a trial is launched. Participating sites should be credentialed to enroll patients in any high-priority trial, and sites with low patient accrual should be eliminated. NCI should allocate a larger portion of its research portfolio to the Cooperative Group Program. However, the trial prioritization and selection process should be strengthened so that only well-designed clinical trials that have the greatest possibility of improving survival and quality of life for cancer patients are undertaken. Launching only the highest-ranked trials would improve quality, speed advances, and ensure that patients are enrolling in the most meaningful and potentially beneficial trials. 
Patient and Physician Participation
A robust clinical trials infrastructure depends on a critical mass of physicians and patients willing to participate. But participation is not the norm today. Participation in clinical trials requires substantial resources and support staff. Clinical investigators and sites are not adequately reimbursed for the costs of participating in Cooperative Group trials. Moreover, the current system does not adequately reward collaborative work, and at academic medical centers, clinical investigation often is accorded less value than either basic research or patient care. Given the limits in funding and capacity of the system, it is unrealistic to expect all or most clinicians to participate in trials, but those who are motivated to do so should be supported and encouraged. NCI and other stakeholders should explore and expand approaches for reducing career and financial concerns, such as providing salary support for protected research time.
Even if patients are eligible for trials and are informed about the option by their physicians, they may decline participation because of financial concerns, as coverage of patient care costs in clinical trials by health insurers is inconsistent. Among other actions, federal and state health benefits plans, private health insurers, and the Centers for Medicare and Medicaid Services should establish consistent payment policies to cover patient care costs (except for specific study-related costs that should be paid for by the drug or device manufacturer) in clinical trials approved through the NCI prioritization mechanism. As a quid pro quo, pri-vate insurers should be able to eliminate coverage of experimental therapies delivered outside of the clinical trial setting, but any such limitation in coverage should not affect off-label use that is backed by evidence from clinical trials published in the scientific literature, as evidence-based off-label use constitutes the standard of care for many cancer therapies and is therefore not experimental.
Conclusion
Improved treatments for cancer will be delayed and patient lives will be lost unnecessarily unless the efficiency and effectiveness of the clinical trials system improves. The implementation of the report's collective recommendations will reinvigorate the NCI Clinical Trials Cooperative Group Program and strengthen its position as a critical component of the translational pathway from scientific discovery to improved treatment outcomes for patients with cancer. Modifying any single element of the Program or the clinical trials process will not suffice; changes across the board are urgently needed. All stakeholders, including physicians, patients, and health care insurers, as well as NCI, other federal agencies, academia, foundations, and industry, must reevaluate their roles and responsibilities in cancer clinical trials and work together to develop an improved, efficient multidisciplinary trials system. The health of nearly 1.5 million patients diagnosed with cancer in the U.S. each year depends on these efforts. 
Statement of Need
On September 20, 2010, cooperative group chairs, through the Coalition of Cancer Cooperative Groups (Coalition), issued a public comment fully endorsing the Institute of Medicine (IOM) analysis "A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program" (April 2010). The statement urged that the IOM's recommendations be adopted in their entirety, and it voiced our willingness as the cooperative group leadership to work with the IOM, National Cancer Institute (NCI), advocacy organizations, and other stakeholders throughout the academic, governmental, and commercial sectors to develop reasoned implementation plans to transform the cooperative group program as recommended.
In this second public comment, we voice our consensus opinion on upcoming changes to the federal funding mechanism by which the cooperative groups will apply for multi-year grant awards from the NCI. The as-yet-to-be-written Funding Opportunity Announcement (FOA) will set forth new criteria by which the groups will be reviewed, ranked, judged, and funded in the future. It is expected that many of the IOM recommendations will coalesce in this FOA; thus, it carries the heavy weight of permanence in that it will set the groups' scientific and operational parameters over the long-term. However, simultaneous to the FOA development, several groups are in the midst of voluntary consolidations (IOM Recommendation #1) whose scientific and operational details are being defined. The irreversible forward momentum of these two parallel timelines has created a need for us to comment publicly.
The NCI has circulated a tentative timeframe for the FOA development, including a period for public comment through July 2011. After the period of public comment concludes, various internal NCI committees and the National Institutes of Health (NIH) will develop the FOA, which is scheduled for release in July 2012. We believe that during the period of public comment, it is imperative to clarify and define the components of a successful re-configuration of the cooperative groups. We have agreed upon a set of guiding principles to ensure that we ourselves advocate consistently for reasoned implementation plans to transform the cooperative group program as recommended. By making these principles publicly available, we trust that we are providing greater clarity for stakeholders during these final days of the public comment period.
The IOM report was the catalyst for various changes to the system that are now underway, and it has generated a new level of enthusiasm within the cooperative group leadership. Over the last several months, group leadership, working with the NCI, has made considerable progress in implementing many of the recommendations in the IOM report, such as increasing the efficiency of group operations, implementing a cross-group information technology (IT) system, and developing plans to consolidate the activities of certain groups into new relationships and entities. There are two over-arching principles on behalf of cancer patients in all of these activities: the first is to provide the framework for the groups to design and conduct innovative, science-driven clinical trials across the clinical research spectrum for the benefit of cancer patients--from advancements in treatment standards and improvements in quality of life to cutting edge early detection, prevention, and diagnostic capabilities. The second principle was well articulated in the IOM report, that "it is imperative to preserve and strengthen unique capabilities of the cooperative group program as a vital component in the NCI's translational research continuum." The cooperative groups are, at their core, multi-disciplinary, multiinstitutional, and multi-disease oriented science-driven clinical research organizations which perform clinical trials designed to move the standard of care forward. The re-configuration should enhance the ability of the groups to perform innovative, sciencedriven clinical trials. To do so, the new review funding criteria for the groups should give the greatest consideration to each group's scientific expertise, followed by what it brings to the network as a whole. This will help ensure that the groups remain focused on improving the outcomes for patients with cancer.
Guiding Principles to
The new review criteria should judge the groups upon their ability to design and perform science-based large Phase II and Phase III studies that complement and balance the more tailored approach of industry toward FDA primary and secondary filings for drug approval, e.g. evaluating new targeted agents across disease types not encompassed in the initial FDA filings; determining the optimum characteristics for patient selections across disease types based upon their molecular and genetic characteristics, and designing trials in selected subsets of patients based upon those characteristics; direct comparisons of competing new therapies or combinations of therapies, some of which may be held by more than one company, or may be nonpharmaceutical therapies; and quality of life research.
In order to perform such studies, the groups must have ready access to agents in development. It is important to acknowledge that while the groups will be judged for their science, and for what they bring to the newly integrated network, it is the role of the NCI to provide ready access to agents within its portfolio.
A major reflection of the quality of science being performed in the groups is their ability to call upon the specific strengths of their membership to produce NCI funding via R01s, P01s, SPORES, contracts, and other publicly and privately funded peer review mechanisms. The new review criteria should stimulate scientific innovation to flow more efficiently from the cancer centers to the cooperative groups by coordinating leadership and prioritizing cancer centers' biomarker-based research, genomics, novel study designs, and promising Phase II studies.
The system is best served by continuing to have independent, academically-based statistical leadership integrated into each group's scientific leadership.
Annotated biospecimens, and the biorepositories that process and hold them, are essential to science-based studies. There are three needs in this area: 1) to maintain the current practice of integrating them into group operational/scientific structures; 2) to provide the IT infrastructure to link biorepositories together aka a virtual biorepository; and 3) to develop a more robust system to provide to biospecimens for peer-reviewed research.
Principle #2 : The cooperative groups will function as an integrated hub for large Phase II and Phase III studies. Cooperative groups are connected by their cross-group scientific and administrative interactions. While each possesses unique capabilities, the cooperative groups are best viewed collectively, within the newly integrated network, as the hub for Phase II and Phase III studies. The NCI should clearly declare that the re-configured cooperative group system is its major vehicle for performing large Phase II and Phase III studies within its translational research continuum.
Together, we are committed to developing, performing, and providing the logistical and infrastructure support for large Phase II and Phase III studies independent of which group originates the study. As a corollary, the new criteria should reward network participation by giving equal credit for all trials in which a group and its members participate.
We are committed to developing a governance structure to manage cross-group scientific and administrative functions, in conjunction with the NCI, which will include developing guidelines for interactions between the group scientific structure and the steering committees, aligning scientific priorities, creating consensus, and enforcing decisions made by the network leadership.
Together, the groups are working with the NCI on an integrated IT infrastructure to support studies performed within the network, including the development of a "virtual biorepository" to facilitate access to biospecimens.
The groups are working with the NCI to continually improve operational efficiencies.
Principle #3 : Flexibility is required to maximize the potential of the restructured system
The cooperative groups are in the process of restructuring, and once consolidations are complete, the groups will look different from one another based upon their need to preserve and enhance areas of scientific and functional expertise. It is likely that some groups will remain as currently structured, some will combine into one entity, and some into a confederation alliance of several entities. The new federal guidelines for grant review should allow groups to make their own decisions about the formation of their structures-scientifically and operationally.
Flexibility is needed to preserve and enhance areas of scientific expertise within the groups, e.g. one group may relate more successfully to patients, physicians, researchers, and other people working in a particular disease specialty, or it may be the groups need to form an imaging hub or laboratory to be available for the entire network; flexibility will be required for the groups to determine how such capabilities fit into the entire system.
The new federal funding guidelines should not require excessive homogeneity in the cooperative groups, or in other words, the criteria should not require groups to be too similar in structure, purpose, or capabilities. Otherwise, if every one of the groups looks the same, there will only be a general competition for funding rather than the more optimal mixing and matching of different scientific and functional expertise in the various groups.
Principle #4 : The strong membership culture of the groups is worth preserving
The cooperative groups are member driven networks, which engender a culture of team science, commitment and volunteerism across three core areas of membership: cancer centers and academic sites; Community Cancer Oncology Programs (CCOPs), Minority-Based CCOPs and other community based practices; and patient advocates involved in research. The new review criteria should reward their strong membership culture as follows:
Cancer Centers and Academic Programs : the NCI-designated cancer centers, their clinical investigators, and laboratory programs provide the scientific engine that drives the development and design of Phase II and III studies within the cooperative group system. The reconfigured system should amplify these interactions.
Under the existing structure, the groups and the cancer centers have benefited mutually from their scientific interactions, e.g. during the last five years 66 RO1s, 6 P01s and 19 SPOREs relating to group work have been awarded to cancer center investigators.
The entire NCI clinical research infrastructure including the cancer centers, R01 and related grants, SPOREs, Program Projects, and the reconfigured cooperative group system must be aligned accordingly to maximize the functional interactions among these programs. We endorse the recommendations of the Ad Hoc Guidelines Harmonization Working Group as presented to the Clinical Trials and Translational Research Advisory Committee (CTAC), and support their earliest possible implementation.
The U10 grant mechanism currently provides an integral connection between the scientific programs of the cooperative groups, cancer centers, and academic institutions; the number of U10 grants in the program should be increased so that additional qualifying institutions can connect to the groups. U10 Principal Investigators and individuals with senior leadership positions within the cooperative groups should be recognized in the senior leadership structure of the cancer centers, and the science they perform within the groups should be acknowledged and rewarded in the cancer center review process. The cancer center core grants should add metrics of success and impact for cooperative group participation via senior leadership positions and participation in active committee membership positions.
In order to increase opportunities for young investigators to develop and lead clinical trials in the groups, we recommend that both the cancer center core grants and cooperative grant mechanism add aligned metrics of success and impact in the area of "career development."
Community-Based Researchers : CCOPs, Minority-Based CCOPs (MBCCOPs), and community practices affiliated with the cooperative groups are an integral component of the existing system and account for over half of the accrual onto group studies. Community-based researchers view the cooperative group structure as their scientific "home" where they can participate at all levels. They are best served by a cooperative group structure that is multidisciplinary, multi-institutional and multi-disease oriented. The new review criteria should preserve and strengthen their membership ties with the groups.
• The current structure provides the opportunity for CCOPs and MBCCOPs to align primarily with one cooperative group, but also allows them to participate in the activities of groups of their choosing through the Expanded Participation Project; this practice should continue.
• To provide a stable funding base, high accruing community practices should be provided the opportunity to receive increased per-case reimbursement and infrastructure support through an expanded U10 mechanism, or other such federally funded mechanisms. This is not currently the practice.
• The groups should continue to support, through the CCOP mechanism, risk assessment, early detection, prevention, symptom intervention, health outcomes, and special populations research.
Cooperative Group Patient Advocates : Approximately 100 individuals serve voluntarily as patient advocates in research across the groups; in each, advocates are involved in all aspects of study development, execution, and trial monitoring. The reconfigured cooperative group system must maintain the integral function of patient advocates in its scientific structure.
We recommend that the consolidation of some of the groups should not result in a substantial reduction in the number of advocates who participate in the groups.
The high level of involvement of the advocates in all phases of trial development and execution should be maintained.
In the newly configured system, patient advocates who participate in disease steering committees, SPORES and other parts of the integrated network, would benefit from having increased access to, and interaction with, the cooperative group advocates. Currently, functional interactions among the cooperative group advocates occur primarily through a structured program within the Coalition of Cancer Cooperative Groups.
Principle #5 : The study review process should incentivize scientific innovation
In the area of scientific proposal review, we agree that extramural peer review facilitated by the NCI should be employed in assessing scientific proposals, and in helping to define the strategic landscape for a given malignancy. The steering committee approach is in varying stages of development and implementation across diseases; this approach should be evaluated primarily for its ability to encourage and incentivize scientific innovation. The entire concept of task forces should be reconsidered. We are developing a white paper discussing the Steering Committee process and its optimization. Listed here are some top line recommendations:
Steering committees should be charged with reviewing studies, not designing or re-designing them, and the role of the NCI should be facilitative, rather than controlling, in the process.
The entire process should be open and transparent.
Unnecessary layers of review should be eliminated, particularly regarding establishment of multiple task forces.
As noted in Principle 2, in conjunction with the NCI, we are committed to developing a governance structure to manage cross-group scientific and administrative functions. One imperative of the governance structure will be to develop guidelines for interactions with steering committees, particularly those needed to stimulate innovative trial approaches using disease specific markers and novel study designs.
Principle #6 : The viability of the new cooperative group hub is linked to its critical resource needs While it is widely known, accepted, and acknowledged by the IOM report that the cooperative group system is grossly underfunded, we also recognize the enormous economic challenges that face our nation. Unfortunately, the crisis in the economy occurs at a time when we are all committed to re-thinking how we operate and work together to enhance the opportunities for patients to participate in innovative ground-breaking clinical trials. As funding priorities within the NCI, NIH, and the federal government are assessed; it is still important to define the critical needs:
Per Case Reimbursement. Recently, the NCI adjusted the base level funding for large Phase II studies to $5,000/case. The case reimbursement structure for Phase III studies must be addressed in the new federal funding opportunity; the base level funding of $2,000/case has become so non-competitive that it endangers the entire national clinical trials system regardless of its configuration. Current per case reimbursement for Phase III studies does not come close to covering the costs of participation in cooperative group trials. This places a burden upon institutions that participate in cooperative group studies to make up the difference through cost-sharing and dedicated staff members who donate their time-an unsustainable reliance upon volunteerism considering the rising cost of medicine. The case-reimbursement floor for Phase III studies should increase to $4,000, with additional reimbursement set trial-by-trial based on complexity and priority. Whatever the reimbursement for a given trial, the funding level should be the same for high accruing sites, whether they are academically or community based.
Number of U10 Grants. The U10 grant mechanism currently provides an integral connection between the scientific programs of the cooperative groups, cancer centers, and academic institutions; an increase in the number of U10 grants in the program will enable additional qualifying institutions and their researchers currently "outside the system" to become members of the groups.
Investigator Compensation. The U10 grant funding should increase, above and beyond case reimbursement, to adequately support investigators for their scientific participation in the groups.
Common IT Platform. We appreciate the NCI's recent commitment of funds to a cross-group IT platform. Funding is needed for continued development and implementation of the uniform IT infrastructure, which includes protocol authoring, clinical trials data management, and biospecimen management.
Biorepositories. Funding is required to fully support the groups' biorepositories. Three needs described in Principle #1 are restated here: 1) to maintain the current practice of integrating the banks into group operational and scientific structures; 2) to provide the IT infrastructure to link biorepositories together aka a virtual biorepository; and 3) to develop a more robust system to provide to biospecimens for peer-reviewed research.
Principle #7 : Multi-sector involvement generates funding and science that would not otherwise happen
The groups bring significant incremental resources to the publicly funded system. Aside from the increased levels of funding defined above, the federal guidelines must continue to provide the flexibility for the cooperative groups to seek and maintain multisector funding relationships. These relationships provide a critical financial supplement to the federal funding, in support of NCIapproved clinical and laboratory based studies.
Close working relationships with industry yield additional resources, on a trial-by-trial basis, to increase inadequate case reimbursement, support laboratory based integral and integrated biomarker studies, and/or address exploratory laboratory investigations. In the latter example, supplemental funding has led to more precise definition of disease and a better understanding of basic tumor biology.
In addition to industry, the groups successfully generate funds from the non-profit sector, in support of NCI-approved studies relating to specific diseases, supportive care, and survivorship.
The peer review system should reward groups for generating science through their foundations and bringing it to the network. Principle #8 : Applicants for cooperative group funding should possess certain Essential Characteristics
The purpose of the new federal funding guidelines should be to produce excellence in science and ensure groups remain focused on improving the outcomes for patients with cancer. To do so, we recommend that applicants to the upcoming funding opportunity possess the following Essential Characteristics: 
Newly Formed Cancer Cooperative Group Selects Name New group integrates the scientific and operations activities of the Cancer and Leukemia Group B (CALGB), the North Central Cancer Treatment Group (NCCTG) and the American College of Surgeons Oncology Group (ACOSOG)
Alliance for Clinical Trials in Oncology ("Alliance") has been selected as the name for the newly formed cooperative group, which will integrate the scientific and operations functions of the Cancer and Leukemia Group B (CALGB), the North Central Cancer Treatment Group (NCCTG) and the American College of Surgeons Oncology Group (ACOSOG). More than 2,000 members of the three groups selected the name by electronic ballot.
The governing boards of CALGB, NCCTG and ACOSOG have endorsed the proposed Alliance constitution, bylaws and transition plan. The first Alliance Board of Directors Meeting will be held on July 15, 2011, in Chicago. Each group has selected delegates to attend the meeting and establish the governance structure of the new group.
The Alliance scientific program leaders, along with scientific leadership from CALGB, NCCTG and ACOSOG, will meet in September, in Chicago, to define the group's scientific agenda going forward.
The first joint Alliance meeting, which will include all members, will be held November 17-19, 2011, in Chicago.
For more information on Alliance activities, visit the group's Web site at www.Alliancewebsite.org.
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Contacts:
Shawn The groups plan to form an alliance that combines their complementary strengths. The new organization will include three areas of research emphasis: early detection and diagnosis of cancer; biomarker-driven Phase II and Phase III therapeutic studies for multiple cancer types and stages; and genetic, molecular and imaging marker research to predict and monitor treatment response.
As leading research organizations, ECOG and ACRIN's individual programs have significantly contributed to improved clinical care. The new alliance will bring together the organizations' unique capabilities to build a program with expanded scientific scope and depth of expertise. ECOG has strengths in performing large-scale trials with molecular endpoints in major diseases; the results of these studies have changed the treatment of cancer patients, and helped to individualize that therapy. ACRIN's clinical trials encompass the full range of medical imaging research: from landmark cancer screening trials to early phase trials evaluating imaging biomarkers and novel imaging technologies. While maintaining these areas of separate expertise, the alliance will press the tailoring of therapy to the individual patient's tumor, and accelerate the integration of biological advances into clinical practice.
"This partnership offers the research community a new sphere of engagement," says Robert L. Comis, MD, Chair of ECOG. "It will greatly enhance our position in the public and private sectors to perform biomarker-driven studies and develop more innovative clinical trial designs. ACRIN has an exceptional imaging research program and IT infrastructure which can be applied to compile and store not only radiologic images, but also, relevant laboratory based images. Our modality and disease committees will have the opportunity to become involved in the development of cutting edge early detection and diagnostic studies, and ACRIN investigators will benefit from being fully integrated into our therapeutically oriented programs." "We are excited by the ECOG partnership opportunity to develop a unique multidisciplinary organization positioned to study the entire cancer care path from early detection through management of advanced disease," says Mitchell D. Schnall, MD, PhD, ACRIN Network Chair. "We will leverage the complementary scientific expertise of each group to develop multidisciplinary scientific committees to address each of the three emphasis areas for which there will be immediate opportunities for interaction and collaboration. The integration of ECOG and ACRIN patient advocacy and clinical research associate committees will bring together an impressive knowledge base representing the patient perspective and participant recruitment best practices -a significant support for getting the research done."
"Clinical research has been an important component of the American College of Radiology (ACR) for over 40 years, comments Harvey L. Neiman, MD, FACR, the ACR's chief executive officer. "I commend the decision to bring together the extensive resources of ACRIN and ECOG to carry out clinical research that combined has even greater potential to bring forth new scientific discoveries to detect cancer earlier and to improve the care and quality of life of cancer patients."
Transition planning is underway, and group leaders are developing the business, administrative and scientific structures. The new organization will sustain its research portfolio with public and private support. Relative to public funding, the NCI announced last November that it will reorganize its Cooperative Group program to support up to four adult cooperative groups, and will issue a new Funding Opportunity Announcement (FOA) in Spring 2012; the new organization will respond on behalf of ECOG and ACRIN..
About ACRIN
The ACRIN network is made up of investigators from over 100 academic and community-based facilities in the United States and abroad. ACRIN's oncology mission is to develop information through clinical trials of medical imaging that increase the length and quality of life of cancer patients. ACRIN also carries out research through its cardiovascular and neuroscience committees. Its imaging core laboratory supports the imaging operations of the ACRIN enterprise as well as other organizations carrying out imaging research. www.acrin.org. 
About ECOG
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Revitalizing the Nation's Cancer Clinical Trials System I f today's new understandings of cancer biology are to benefit cancer patients on a broad scale, they must be coupled with a modernized system for conducting cancer clinical trials. This system must enable clinical researchers across the nation to acquire tumor specimens and conduct genetic tests on each patient, to efficiently sequence the DNA from those samples, to manage and secure vast quantities of genetic and clinical data, and to identify subsets of patients with tumors that demonstrate changes in specific molecular pathways-pathways that can be targeted by a new generation of cancer therapies. And all of this must be done one patient at a time.
As part of its effort to transform the cancer clinical trials system, NCI asked the Institute of Medicine (IOM) in 2009 to review the Clinical Trials Cooperative Group Program. This program involves a national network of 14,000 investigators currently organized into nine adult Cooperative Groups and one pediatric cooperative group that conduct large-scale cancer clinical trials at 3,100 sites across the U.S. The IOM report, issued in April 2010, noted that the current trials system-established a half-century ago-is inefficient, cumbersome, underfunded, and overly complex. Among a series of recommendations, the report urged that the existing adult cooperative groups be consolidated into a smaller number of groups, each with greater capabilities and the ability to function with the others in a more integrated manner.
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In December 2010, NCI announced its intent to begin consolidating the current nine adult cooperative groups into up to four state-of-the-art entities that will design and perform improved trials of cancer treatments, as well as explore methods of cancer prevention and early detection and study quality-of-life issues and rehabilitation during and after treatment. The sole pediatric cooperative group was created by consolidating four pediatric cooperative groups a number of years ago, and that group will not be affected by the current consolidation effort.
NCI also intends to consolidate nine existing tumor banks into three to give researchers improved access to a nationally integrated tissue resource. Currently, optimal use of tissue specimens from NCI-supported prospective trials is impeded by the lack of a national IT system for locating tissue, the lack of standard operating procedures, and the lack of a transparent process to prioritize the distribution of specimens on a national scale.
The consolidation of the cooperative groups is also intended to improve the efficiencies of operations centers and data management centers, and to facilitate the training of investigators in applying molecularly based approaches to large-scale clinical trials. In addition, NCI envisions using the Cooperative Group Program as a means for preparing the oncology community, including community physicians, for the widespread introduction of molecularly-based therapies.
The consolidation of the Cooperative Group Program is the most recent in a series of changes initiated by NCI, through its Division of Cancer Treatment and Diagnosis and the Coordinating Center for Clinical Trials, to revitalize the nation's cancer clinical trials system. Other transformative changes introduced in recent years include those outlined in a working group report which can be found at http://ccct.cancer.gov/files/OEWG-Report.pdf:
• � Reduce by half the time to initiate new clinical studies and terminate studies not begun within 18 to 24 months of concept approval.
• � Revamp the prioritization process for large phase II and phase III treatment trials by creating disease-specific and modality-specific steering committees.
• � Improve the use and efficiency of the NCI Central Institutional Review Board, which reduced the average time for final sign-off on protocols for national trials from 150 days in 2007 to 42 days in 2010.
• � Increase reimbursement to clinical trials sites. Although I am new to this position, I am not new to cancer research or to the NCI. I received my scientific training here more than 40 years ago, started to work on cancer-causing viruses shortly thereafter, and have been supported by NCI funds throughout my career. In these intervening years, I have witnessed profound changes in our knowledge about the biology of cancer. When I began to study animal models of cancer in the early 1970s, the collective understanding of the origins and progression of cancer was negligible; now we are able to describe such events in minute detail at the molecular level. This transformation has been accompanied by gradual-and occasionally dramatic-improvements in the control of human cancer. In an increasing number of cancers, new concepts about the biology of cancer are now driving beneficial changes in the ways we prevent, diagnose, and treat disease.
The importance of the NCI throughout this rich history can best be appreciated by considering the amazing diversity of the approaches it has undertaken to control cancer-through basic research on normal cells, genes, and proteins; through studies of the pathogenesis of various forms of cancer; and through efforts to improve the prevention, diagnosis, and treatment of cancers.
In the first half of this report, we have tried to convey the depth of these enterprises, while emphasizing at least three big ideas. First, cancer constitutes a complex set of diseases. It is not simply one disease that happens to afflict many organs of the body; it is, instead, many different disorders that display some common themes, including mutations in many important genes, alterations in essential cell functions, and novel interactions with the cellular environment in which tumors grow. Second, cancers can be controlled in many different ways. As reflected in their biological complexity, cancers invite several strategies to improve control. These include a number of approaches to prevention, multiple methods to screen for early stages of carcinogenesis, more precise diagnostic tests, and better
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| therapies. The improved treatments are based on knowledge of specific genetic changes in cancer cells, the functions of the immune system, the susceptibilities of cancer cells to various drugs and radiotherapy, and an understanding of the symptoms and complications of these diseases.
Third, advances against cancer that benefit people depend on science of many kinds. Progress in the control of cancer has required new knowledge from the many fields of research that the NCI supports-from molecular and cell biology, genetics, virology, immunology, and chemistry; from animal models of cancer; from the behavior and biology of human beings; and from many other directions. In brief, cancer represents one of the greatest challenges to the strength of modern medical science.
My colleagues and I have chosen to illustrate these ideas, and the complexity they embody, by describing recent progress made against six kinds of cancer, chosen somewhat arbitrarily from a much larger repertoire of successes. We acknowledge that none of these six stories is over; in all situations, we have much more to do. But each narrative reveals a promising path to further progress.
The men and women who have achieved these successes and who are poised to extend them represent our greatest resource. With the additional funds requested here, their ambitions and talents can be unleashed, ensuring that the NCI can take the greatest possible advantage of the opportunities created by its remarkable history. It should be noted that we have carefully reviewed our current expenditures and have found important efficiencies and savings. The current services increase is the amount that will be required to sustain NCI programs, restore some of the funding cuts that have been implemented over the past several fiscal years, and provide for some minimal growth. Noncompeting Research Project Grants (RPGs) would be funded at committed levels, the number of competing RPGs would be maintained at the FY 2010 level, and most other mechanisms would receive sufficient increases to cover cost of living adjustments based on the Biomedical Research and Development Price Index (BRDPI). This budget level also includes funds to make critically needed capital repairs and improvements at the NCI-Frederick Federally Funded Research and Development Center.
The additional funds requested reflect the Institute's assessment of where more funding will make the greatest difference in reducing cancer incidence and mortality. Together, with growing the research grants portfolio, these new or expanded initiatives-cancer genomics, transformation of the clinical trials system, and more effective translation of research results to clinical utility-offer the greatest current hope of advances against cancer.
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